Impact of routine assessment of health-related quality of life coupled with therapeutic information on compliance with endocrine therapy in patients with non-metastatic breast cancer: protocol for a randomized controlled trial.

Fiche publication

Date publication

juin 2020

Journal

Trials

Auteurs

Membres identifiés du Cancéropôle Est :
Pr COUTANT Charles , Dr DABAKUYO-YONLI Sandrine , Dr PAGET-BAILLY Sophie , Dr DESMOULINS Isabelle , Dr MAMGUEM KAMGA Ariane

Tous les auteurs :
Mamguem Kamga A, Di Martino C, Anota A, Paget-Bailly S, Coutant C, Arveux P, Desmoulins I, Dabakuyo-Yonli TS

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32546198

Résumé

Despite its proven efficacy in reducing recurrence and improving survival, adherence to endocrine therapy (ET) is suboptimal in women with breast cancer (BC). Health-related quality of life (HRQoL) in BC has been widely studied and many positive effects have been highlighted. Recently, a link between HRQoL and compliance with ET has been suggested, which would suggest a potential role for HRQoL assessment in improving compliance with ET. With the advent of digital technologies, electronic collection of HRQoL on a tablet is now possible. Thus, we hypothesize that systematic HRQoL assessment (using a tablet, prior to each consultation, with presentation of scores to clinicians) coupled with therapeutic information could have an impact on 12-month compliance with ET in patients with non-metastatic BC.